The Burden of Human Bocavirus 1 in Hospitalized Children With Respiratory Tract Infections.
children
hospitalization rates
human bocavirus
respiratory tract infections
seasonality
Journal
Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
16
12
2022
accepted:
27
04
2023
medline:
2
6
2023
pubmed:
26
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Human bocavirus 1 (HBoV1) is frequently codetected with other viruses, and detected in asymptomatic children. Thus, the burden of HBoV1 respiratory tract infections (RTI) has been unknown. Using HBoV1-mRNA to indicate true HBoV1 RTI, we assessed the burden of HBoV1 in hospitalized children and the impact of viral codetections, compared with respiratory syncytial virus (RSV). Over 11 years, we enrolled 4879 children <16 years old admitted with RTI. Nasopharyngeal aspirates were analyzed with polymerase chain reaction for HBoV1-DNA, HBoV1-mRNA, and 19 other pathogens. HBoV1-mRNA was detected in 2.7% (130/4850) samples, modestly peaking in autumn and winter. Forty-three percent with HBoV1 mRNA were 12-17 months old, and only 5% were <6 months old. A total of 73.8% had viral codetections. It was more likely to detect HBoV1-mRNA if HBoV1-DNA was detected alone (odds ratio [OR]: 3.9, 95% confidence interval [CI]: 1.7-8.9) or with 1 viral codetection (OR: 1.9, 95% CI: 1.1-3.3), compared to ≥2 codetections. Codetection of severe viruses like RSV had lower odds for HBoV1-mRNA (OR: 0.34, 95% CI: 0.19-0.61). The yearly lower RTI hospitalization rate per 1000 children <5 years was 0.7 for HBoV1-mRNA and 8.7 for RSV. True HBoV1 RTI is most likely when HBoV1-DNA is detected alone, or with 1 codetected virus. Hospitalization due to HBoV1 LRTI is 10-12 times less common than RSV.
Sections du résumé
BACKGROUND
BACKGROUND
Human bocavirus 1 (HBoV1) is frequently codetected with other viruses, and detected in asymptomatic children. Thus, the burden of HBoV1 respiratory tract infections (RTI) has been unknown. Using HBoV1-mRNA to indicate true HBoV1 RTI, we assessed the burden of HBoV1 in hospitalized children and the impact of viral codetections, compared with respiratory syncytial virus (RSV).
METHODS
METHODS
Over 11 years, we enrolled 4879 children <16 years old admitted with RTI. Nasopharyngeal aspirates were analyzed with polymerase chain reaction for HBoV1-DNA, HBoV1-mRNA, and 19 other pathogens.
RESULTS
RESULTS
HBoV1-mRNA was detected in 2.7% (130/4850) samples, modestly peaking in autumn and winter. Forty-three percent with HBoV1 mRNA were 12-17 months old, and only 5% were <6 months old. A total of 73.8% had viral codetections. It was more likely to detect HBoV1-mRNA if HBoV1-DNA was detected alone (odds ratio [OR]: 3.9, 95% confidence interval [CI]: 1.7-8.9) or with 1 viral codetection (OR: 1.9, 95% CI: 1.1-3.3), compared to ≥2 codetections. Codetection of severe viruses like RSV had lower odds for HBoV1-mRNA (OR: 0.34, 95% CI: 0.19-0.61). The yearly lower RTI hospitalization rate per 1000 children <5 years was 0.7 for HBoV1-mRNA and 8.7 for RSV.
CONCLUSIONS
CONCLUSIONS
True HBoV1 RTI is most likely when HBoV1-DNA is detected alone, or with 1 codetected virus. Hospitalization due to HBoV1 LRTI is 10-12 times less common than RSV.
Identifiants
pubmed: 37099765
pii: 7143570
doi: 10.1093/jpids/piad027
pmc: PMC10231390
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
282-289Subventions
Organisme : Central Norway Regional Health Authority
ID : 96987/2008
Organisme : Trondheim University Hospital
ID : 13/8985-119
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.
Références
J Med Virol. 2016 Dec;88(12):2052-2058
pubmed: 27124519
Pediatr Infect Dis J. 2008 Oct;27(10):897-902
pubmed: 18756188
Emerg Infect Dis. 2013 Apr;19(4):574-80
pubmed: 23628409
J Infect Dis. 2021 Dec 1;224(11):1900-1906
pubmed: 34009376
Pediatr Infect Dis J. 2011 Apr;30(4):279-83
pubmed: 21057374
J Infect Dis. 2017 May 15;215(10):1551-1557
pubmed: 28379530
Pediatr Infect Dis J. 2008 Apr;27(4):358-60
pubmed: 18316984
Pediatr Infect Dis J. 2016 May;35(5):471-6
pubmed: 26766144
Front Public Health. 2021 Jul 05;9:691163
pubmed: 34291031
Front Pediatr. 2022 Aug 11;10:935483
pubmed: 36034546
J Infect Dis. 2017 Sep 15;216(6):688-696
pubmed: 28934425
J Infect Dis. 2007 Apr 1;195(7):1038-45
pubmed: 17330795
Biomed Environ Sci. 2014 Nov;27(11):841-8
pubmed: 25374017
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12891-6
pubmed: 16118271
Lancet Child Adolesc Health. 2019 Jun;3(6):418-426
pubmed: 30948251
PLoS One. 2015 Aug 12;10(8):e0135640
pubmed: 26267139
J Med Virol. 2012 Jan;84(1):99-108
pubmed: 22028039
BMC Infect Dis. 2018 Jul 16;18(1):329
pubmed: 30012099
Influenza Other Respir Viruses. 2021 Jul;15(4):488-494
pubmed: 33715290
Clin Infect Dis. 2015 Oct 15;61(8):1217-24
pubmed: 26245665
J Infect Dis. 2017 Jul 1;216(1):110-116
pubmed: 28838133
J Infect Dis. 2010 Jun 1;201(11):1625-32
pubmed: 20415535
J Clin Virol. 2019 Nov;120:17-19
pubmed: 31521013
Front Pediatr. 2022 Jan 05;9:759213
pubmed: 35071128
PLoS One. 2012;7(8):e42136
pubmed: 22870291
Emerg Infect Dis. 2009 Sep;15(9):1423-30
pubmed: 19788810
Int J Pediatr Otorhinolaryngol. 2014 Oct;78(10):1655-61
pubmed: 25128448
J Infect Dis. 2019 Apr 8;219(8):1198-1206
pubmed: 30418633
J Clin Virol. 2007 Nov;40(3):229-35
pubmed: 17851126
Emerg Infect Dis. 2008 Feb;14(2):217-21
pubmed: 18258113
J Infect Dis. 2015 Aug 15;212(4):516-24
pubmed: 25632039
J Infect Dis. 2019 Jul 19;220(4):589-593
pubmed: 31001641
J Clin Virol. 2010 Nov;49(3):158-62
pubmed: 20833582
BMC Pediatr. 2018 Jul 21;18(1):240
pubmed: 30031377